Nicox S.A. (0RCQ.L)

0.4045 +0.0025 (+0.62%) At close: 03:51PM BST

Nicox S.A.

2405 Route Des Dolines
Drakkar 2 Bât D
Valbonne 06560
France
33 4 97 24 53 00
https://www.nicox.com

Sector(s): 
Industry: 
Full-time employees: 28

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michele Garufi Ph.D.	Co-Founder & Director	441.62k	N/A	1954
Dr. Gavin M. Spencer	Chief Executive Officer	N/A	N/A	1970
Ms. Sandrine Gestin	Vice President of Finance	N/A	N/A	1967
Mr. Doug Hubatsch	Executive VP & Chief Scientific Officer	N/A	N/A	1967
Dr. Ramesh Krishnamoorthy	Senior Director and Head of Late Stage CMC & Quality Control	N/A	N/A	N/A
Dr. Jose Boyer	Consultant	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

Corporate governance

Nicox S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.